PDCD1 and neoplasm: Adding ibrutinib to CAR-T cell-target cell co-cultures significantly reduces exhaustion marker expression, such as PD-1, TIM-3, LAG-3, and CTLA-4 [76], indicating CAR-T cell exhaustion reduction is key in enhancing anti-tumor efficacy in combination therapy.